[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.
Read more A true entrepreneurial project and a rare occurrence in biotechnology, Oncodesign’s capital is mainly held by its managers, including Dr. Philippe Genne, CEO and Founder of the company. The interests of management and shareholders remain perfectly aligned.
€ millions | FY21 | FY20 | FY19 | FY18 | FY17 |
---|---|---|---|---|---|
Turnover Other operating income | 31.3 4.9 | 25.5 13.0 | 26.9 12.6 | 20.1 12.7 | 14.3 11.6 |
Total operating income Total costs | 36.2 (37.1) | 38.5 (37.0) | 39.5 (38.8) | 32.8 (36.6) | 25.9 (30.3) |
Operating income Financial expenses and income Exceptional expenses and income Income tax Amortization of negative goodwill | (1.0) | 1.5 (0.6) (0.2) 0.4 1.0 | 0.7 (0.2) (0.1) 0.3 1.0 | (3.8) (0.3) 0.1 (0.0) 0.8 | (4.4) (0.2) (1.2) (0.3) 1.0 |
net Consolidated Income / Loss | (0.3) | 2.1 | 1.6 | (3.1) | (5.0) |
Investments in R&D | 7.4 | 10.8 | 11.1 | 12.0 | 13.9 |
Cash position at 31.12.N | 25.4 | 28.7 | 10.5 | 10.1 | 11.5 |
Staff | 231 | 238 | 233 | 232 | 180 |
20/21 | 19/20 | 18/19 | 17/18 |
---|---|---|---|
22% -62% | -5% 3% | 34% -1% | 41% 9% |
-6% 0% | -2% -5% | 20% 6% | 27% 21% |
-2.5M€ | +0.8M€ ns 62% | +4.5M€ ns 25% | +0.6M€ ns -20% |
-2.5M€ | +0.5M€ | +4.8M€ | +1.8M€ |
-32% | -3% | -8% | -14% |
-3.3M€ | +18.2M€ | +0.5M€ | +1.4M€ |
Last updated: 2020
These key figures are updated according to the financial calendar